Efficacy and safety of Risankizumab, a p19-selective IL-23 inhibitor, in moderate to severe UC: IBDnet

Title: Efficacy and safety of Risankizumab, a p19-selective IL-23 inhibitor, in moderate to severe UC
Study drug: Risankizumab
Sponsor: AbbVie
Participating centers and contact: Insel Bern, PD Dr. med. Pascal Juillerat (Pascal.Juillerat@insel.ch)
Target population: Moderate to severe UC
Primary outcome:
Inclusion criteria:
Exclusion criteria:
More information:

Efficacy and safety of Risankizumab, a p19-selective IL-23 inhibitor, in moderate to severe UC